Abstract
Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed.
Original language | English |
---|---|
Pages (from-to) | 520-527 |
Number of pages | 8 |
Journal | Movement Disorders |
Volume | 33 |
Issue number | 4 |
Early online date | 24 Mar 2018 |
DOIs | |
Publication status | Published - Apr 2018 |
Keywords
- clinical trials
- mild cognitive impairment
- nonpharmacologic
- Parkinson disease
- pharmacologic